Skip to main content
. 2024 Feb 6;15:1337396. doi: 10.3389/fimmu.2024.1337396

Table 4.

Adverse events.

Adverse events Observation group(n=29)
Grade 1-2 AEs ≥ Grade 3 AEs
Pruritus, Rash 41.38% (12) 3.45% (1)
Hypertension 34.48% (10) 0
Abdominal pain, Diarrhea 31.03% (9) 6.90% (2)
Fatigue 31.03% (9) 3.45% (1)
Increased AST or ALT 27.59% (8) 0
Dry skin 20.69% (6) 3.45% (1)
Decreased appetite 17.24% (5) 0
Stomatitis 6.90% (2) 0

AST, aspartate aminotransferase; ALT,alanine aminotransferase.